Giroux S, Dubé-Linteau A, Cardinal G, Labelle Y, Laflamme N, Giguère Y, Rousseau F
Unité de Recherche en Génétique Humaine et Moléculaire, Centre de Recherche de l'Hôpital St-François d'Assise du Centre Hospitalier Universitaire de Québec, Québec, Canada.
Clin Genet. 2007 Jun;71(6):569-75. doi: 10.1111/j.1399-0004.2007.00809.x.
Inherited deficiency of medium-chain acyl-CoA dehydrogenase (MCAD) is a severe, sometimes fatal disorder. A single mutation in the MCAD gene, 985A>G, is involved in approximately 90% of cases. To evaluate the relevance of implementing a systematic population-based screening program in the province of Quebec using a biochemical test, we measured the prevalence of this mutation in a set of anonymous newborn samples from the Quebec City area, a region where the majority of its inhabitants are French-Canadians. An allele-specific polymerase chain reaction assay was designed and used to detect the mutation in 7143 DNA samples obtained from consecutive anonymous newborns. Pools of eight DNA samples were genotyped in parallel for the same mutation to validate this pooling strategy. The allelic frequency of the MCAD 985A>G mutation was found to be 0.71% and the carrier frequency 1:71 (95% confidence interval 1:55 to 1:98). This estimate predicts a homozygous frequency of 1:19,837. Ninety-nine heterozygous carriers and one homozygous individual were identified out of 7143 samples. There was 100% concordance between the individual and pooled analyses, and the pooling strategy reduced the total genotyping costs by approximately 70%. The carrier frequency estimated for this population is similar to other northwestern European populations and would support implementation of systematic newborn screening (such as tandem mass spectrometry screening) for this disease. Pooling DNA samples followed by genotyping appears to be cost-effective for estimating prevalence of rare mutations.
中链酰基辅酶A脱氢酶(MCAD)遗传性缺乏是一种严重的、有时甚至致命的疾病。MCAD基因中的一个单一突变,即985A>G,约90%的病例与之相关。为了评估在魁北克省使用生化检测实施基于人群的系统筛查项目的相关性,我们在一组来自魁北克市地区的匿名新生儿样本中测量了该突变的患病率,该地区的大多数居民是法裔加拿大人。设计了一种等位基因特异性聚合酶链反应检测方法,并用于检测从连续的匿名新生儿获得的7143份DNA样本中的突变。将8个DNA样本合并进行相同突变的平行基因分型,以验证这种合并策略。发现MCAD 985A>G突变的等位基因频率为0.71%,携带者频率为1:71(95%置信区间为1:55至1:98)。这一估计预测纯合子频率为1:19,837。在7143份样本中,共鉴定出99名杂合子携带者和1名纯合子个体。个体分析和合并分析之间的一致性为100%,合并策略使总基因分型成本降低了约70%。该人群估计的携带者频率与其他西北欧人群相似,这将支持对该疾病实施系统的新生儿筛查(如串联质谱筛查)。合并DNA样本后进行基因分型似乎对于估计罕见突变的患病率具有成本效益。